Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

AGEN

Agenus Inc

May 13 • 04:00PM ET

11.09

Dollar change +0.60
Percentage change 5.72	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC FESM IWO

Index	RUT	P/E	-	EPS (ttm)	-12.62	Insider Own	4.95%	Shs Outstand	21.00M	Perf Week	-14.36%
Market Cap	232.89M	Forward P/E	-	EPS next Y	-8.68	Insider Trans	102.04%	Shs Float	19.96M	Perf Month	36.07%
Income	-239.61M	PEG	-	EPS next Q	-1.64	Inst Own	53.77%	Short Float	16.22%	Perf Quarter	-31.48%
Sales	161.42M	P/S	1.44	EPS this Y	35.33%	Inst Trans	-	Short Ratio	3.99	Perf Half Y	-26.40%
Book/sh	-9.59	P/B	-	EPS next Y	2.78%	ROA	-71.52%	Short Interest	3.24M	Perf Year	-60.39%
Cash/sh	2.52	P/C	4.41	EPS next 5Y	-	ROE	-	52W Range	4.78 - 42.60	Perf YTD	-33.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.79%	ROI	-	52W High	-73.97%	Beta	1.26
Dividend TTM	-	Quick Ratio	0.24	Sales past 5Y	98.93%	Gross Margin	90.51%	52W Low	132.25%	ATR (14)	1.47
Dividend Ex-Date	-	Current Ratio	0.24	EPS Y/Y TTM	22.36%	Oper. Margin	-85.64%	RSI (14)	52.42	Volatility	13.64% 19.55%
Employees	389	Debt/Eq	-	Sales Y/Y TTM	69.94%	Profit Margin	-148.44%	Recom	1.20	Target Price	44.25
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	29.41%	Payout	-	Rel Volume	0.49	Prev Close	10.49
Sales Surprise	-40.63%	EPS Surprise	5.20%	Sales Q/Q	22.28%	Earnings	May 07 BMO	Avg Volume	811.08K	Price	11.09
SMA20	16.44%	SMA50	4.13%	SMA200	-33.92%	Trades		Volume	394,788	Change	5.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-23	Initiated	Robert W. Baird	Outperform	$8
Jun-06-23	Initiated	Robert W. Baird	Outperform	$60 → $80
Feb-28-23	Resumed	H.C. Wainwright	Buy	$8
Sep-28-22	Initiated	SMBC Nikko	Outperform	$5
Dec-16-21	Initiated	H.C. Wainwright	Buy	$12
Nov-19-19	Resumed	B. Riley FBR	Buy	$6
Apr-22-19	Initiated	B. Riley FBR	Buy
Oct-28-16	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $5
Oct-27-16	Reiterated	Maxim Group	Buy
Mar-11-16	Upgrade	Maxim Group	Hold → Buy	$7
Dec-16-15	Initiated	Jefferies	Buy
Oct-27-15	Downgrade	Maxim Group	Buy → Hold
Jul-27-15	Reiterated	MLV & Co	Buy	$9 → $11
Jun-11-15	Initiated	Oppenheimer	Outperform	$14
Jan-12-15	Reiterated	Maxim Group	Buy	$10 → $11
Jan-09-15	Reiterated	MLV & Co	Buy	$6 → $9
Jan-09-15	Reiterated	Maxim Group	Buy	$10 → $11
Dec-19-14	Reiterated	Maxim Group	Buy	$8 → $10
May-08-14	Reiterated	Maxim Group	Buy	$17 → $11
Mar-14-14	Reiterated	MLV & Co	Buy	$9 → $11

Show Previous Ratings

May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:11AM	Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:09AM	Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-07-24 05:45PM	Agenus (AGEN) Q1 2024 Earnings Call Transcript (Motley Fool) -7.26%
01:52PM	Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading (MT Newswires)
12:24PM	Loading…
12:24PM	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates (MT Newswires)
09:00AM	Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:56AM	Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments (GuruFocus.com)
07:59AM	Agenus: Q1 Earnings Snapshot (Associated Press Finance)
07:40AM	Agenus Reports First Quarter 2024 Results (Business Wire)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
May-01-24 07:30AM	Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire) +9.41%
Apr-28-24 08:30AM	Up 40%: Is This Red-Hot Growth Stock Still a Buy? (Motley Fool)
Apr-24-24 10:00AM	Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting (Business Wire) +14.86%
Apr-23-24 07:30AM	Agenus to Provide First Quarter 2024 Financial Report and Corporate Update (Business Wire) +11.96%
04:17AM	Loading…
Apr-22-24 04:17AM	Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock? (Zacks) +8.66%
Apr-12-24 07:30AM	Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer (Business Wire) -8.12%
Apr-08-24 03:34AM	Down 75%. Is Agenus Stock a Buy on the Dip? (Motley Fool) -7.58%
Apr-05-24 04:30PM	Agenus Announces Reverse Stock Split of Common Stock (Business Wire)
Apr-03-24 04:19AM	2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? (Motley Fool)
Mar-24-24 04:05PM	3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million (InvestorPlace)
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 02:11PM	Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.95%
Mar-14-24 01:30PM	Agenus (AGEN) Q4 2023 Earnings Call Transcript (Motley Fool) -8.94%
08:51AM	Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline (GuruFocus.com)
07:39AM	Agenus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Fourth Quarter and Full Year 2023 Results (Business Wire)
Mar-06-24 07:30AM	Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 (Business Wire)
Mar-05-24 04:30PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 07:30AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (Business Wire) -10.81%
07:30AM	Loading…
Feb-26-24 07:30AM	Agenus to Participate in Leerink Partners Global Biopharma Conference (Business Wire) +6.36%
Feb-15-24 06:38PM	Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today (Motley Fool) -29.54%
07:02AM	Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design (PR Newswire)
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace)
Jan-31-24 07:30AM	Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +5.32%
Jan-26-24 03:57PM	3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 (InvestorPlace) +10.47%
Jan-22-24 07:30AM	Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population (Business Wire)
Jan-05-24 04:30PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 07:30AM	Agenus to Participate in B. Riley Healthcare Conference (Business Wire)
Dec-24-23 09:45AM	2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street (Motley Fool)
Dec-20-23 07:30AM	Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024 (Business Wire)
Dec-11-23 07:30AM	Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program (Business Wire) -8.91%
Nov-07-23 06:55AM	Agenus Inc (AGEN) Reports Q3 2023 Results: Revenue of $24.3 Million and Net Loss of $64.5 Million (GuruFocus.com)
06:41AM	Agenus: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agenus Reports Third Quarter 2023 Results (Business Wire)
Oct-26-23 09:05AM	Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update (Business Wire)
Oct-22-23 12:00PM	Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma (Business Wire)
Oct-21-23 04:15AM	ESMO 2023: Agenus Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes (Business Wire)
Oct-10-23 07:30AM	Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer (Business Wire) +5.94%
Oct-05-23 07:30AM	Agenus To Host BOT/BAL Program Update at ESMO 2023 (Business Wire)
Sep-01-23 04:30PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-28-23 08:30AM	3 Magnificent Growth Stocks to Buy on the Dip (Motley Fool) +5.34%
07:30AM	Agenus to Participate in September Investor Conferences (Business Wire)
Aug-24-23 09:54AM	Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7% (Zacks) -5.00%
Aug-23-23 02:00PM	Watertown biotech shares spike after accidental data publication at Roche (American City Business Journals) -7.28%
01:16PM	Lexington biotech lays off 91 as it narrows focus (American City Business Journals)
08:00AM	Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers (Business Wire)
Aug-18-23 04:27AM	Q2 2023 Xilio Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.36%
Aug-17-23 10:04AM	Billionaire Steve Cohen Loads Up on These 2 Strong Buy Penny Stocks Heres Why Wall Street Sees Over 500% Upside Potential (TipRanks)
Aug-09-23 08:30AM	SaponiQx Announces Breakthrough in Scaling Up of STIMULON Cultured Plant Cell Adjuvant (Business Wire)
Aug-08-23 10:00AM	Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics (Zacks) -8.09%
08:19AM	Agenus: Q2 Earnings Snapshot (AP Finance)
07:30AM	Agenus Reports Second Quarter 2023 Results (Business Wire)
Aug-03-23 05:25PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-23 07:30AM	Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023 (Business Wire) +5.52%
Jul-26-23 07:30AM	Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update (Business Wire)
Jul-20-23 07:30AM	Agenus Expands Executive Leadership Team (Business Wire)
Jul-10-23 07:58AM	With 52% institutional ownership, Agenus Inc. (NASDAQ:AGEN) is a favorite amongst the big guns (Simply Wall St.) +10.98%
Jun-30-23 11:15AM	ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer (Business Wire)
Jun-26-23 10:15AM	2 Low-Priced Stocks That Could Make You Richer (Motley Fool) -5.20%
Jun-06-23 07:46AM	Even after rising 19% this past week, Agenus (NASDAQ:AGEN) shareholders are still down 53% over the past three years (Simply Wall St.) +6.94%
Jun-05-23 09:49AM	Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO (Business Wire) +8.12%
07:30AM	Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
May-25-23 07:30AM	Agenus to Participate in Jefferies Healthcare Conference (Business Wire)
May-10-23 06:11AM	Broker Revenue Forecasts For Agenus Inc. (NASDAQ:AGEN) Are Surging Higher (Simply Wall St.)
May-09-23 07:00PM	Agenus (AGEN) Q1 2023 Earnings Call Transcript (Motley Fool) -5.66%
09:15AM	Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:10AM	Agenus: Q1 Earnings Snapshot (AP Finance)
08:00AM	Agenus Provides Corporate Update and First Quarter 2023 Financial Results (Business Wire)
May-03-23 09:08AM	Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI (Business Wire) +5.67%
Apr-26-23 10:35AM	Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting (Business Wire)
Apr-25-23 07:30AM	Agenus to Provide Corporate Update and First Quarter 2023 Financial Report (Business Wire) -5.75%
Apr-24-23 07:30AM	Agenus to Participate in May Investor Conferences (Business Wire)
Apr-18-23 11:20AM	Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug (Zacks)
Apr-17-23 01:55PM	These 3 Nasdaq Stocks Are on Fire Today: Here's Why (Motley Fool) +15.86%
08:47AM	Lacklustre Performance Is Driving Agenus Inc.'s (NASDAQ:AGEN) Low P/S (Simply Wall St.)
07:30AM	Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer (Business Wire)
Apr-12-23 04:30PM	Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer (GlobeNewswire)
Apr-04-23 03:53PM	Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today (Motley Fool) -5.10%
Mar-30-23 08:41AM	Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics (Business Wire) -7.05%
Mar-27-23 03:12PM	Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer (Benzinga)
09:45AM	Agenus Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer (Business Wire)
Mar-23-23 12:21PM	Why Agenus Stock Is Slumping This Week (Motley Fool)
Mar-17-23 04:31AM	Agenus Inc. (NASDAQ:AGEN) Q4 2022 Earnings Call Transcript (Insider Monkey) -7.10%
Mar-14-23 04:00PM	Agenus (AGEN) Q4 2022 Earnings Call Transcript (Motley Fool)
08:45AM	Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives (GlobeNewswire)
Mar-12-23 08:29PM	Agenus Cancels Conference Call to Discuss the Companys Minority Cash Holdings at SVB in Light of Governments SVB Deposit Access Announcement (GlobeNewswire)
Mar-11-23 11:24AM	Agenus Schedules Conference Call to Discuss the Companys Minority Cash Holdings at SVB (GlobeNewswire)
Feb-28-23 07:30AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report (GlobeNewswire)

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARMEN GARO H	See Remarks	Feb 15 '24	Buy	0.65	500,000	324,050	625,969	Feb 15 06:59 PM
WIINBERG ULF	Director	Nov 15 '23	Buy	0.76	25,000	19,000	124,063	Nov 17 04:22 PM
AGENUS INC	10% Owner	Oct 16 '23	Buy	1.10	429	472	21,772,863	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 13 '23	Buy	1.10	19,373	21,310	21,772,434	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 12 '23	Buy	1.10	3,173	3,488	21,753,061	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 04 '23	Buy	1.09	15,001	16,380	21,749,888	Oct 06 04:26 PM
AGENUS INC	10% Owner	Aug 29 '23	Buy	1.52	29,678	45,016	21,734,887	Aug 31 05:53 PM
AGENUS INC	10% Owner	Aug 28 '23	Buy	1.45	12,808	18,570	21,705,209	Aug 28 05:15 PM
AGENUS INC	10% Owner	Aug 24 '23	Buy	1.54	170,244	262,908	21,692,401	Aug 28 05:15 PM

Open in Screener

INKT

MiNK Therapeutics Inc

May 13 • 04:00PM ET

0.9798

Dollar change +0.0798
Percentage change 8.87	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

INKT MiNK Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.65	Insider Own	71.34%	Shs Outstand	34.60M	Perf Week	4.16%
Market Cap	34.00M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	0.00%	Shs Float	9.95M	Perf Month	-0.50%
Income	-22.46M	PEG	-	EPS next Q	-0.15	Inst Own	2.94%	Short Float	0.88%	Perf Quarter	4.17%
Sales	0.00M	P/S	-	EPS this Y	13.39%	Inst Trans	32.08%	Short Ratio	0.90	Perf Half Y	-11.73%
Book/sh	-0.52	P/B	-	EPS next Y	-6.33%	ROA	-172.60%	Short Interest	0.09M	Perf Year	-39.52%
Cash/sh	0.10	P/C	10.09	EPS next 5Y	-	ROE	-1238.95%	52W Range	0.75 - 3.34	Perf YTD	-8.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.37%	ROI	-	52W High	-70.66%	Beta	0.02
Dividend TTM	-	Quick Ratio	0.32	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	30.64%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	0.32	EPS Y/Y TTM	21.35%	Oper. Margin	0.00%	RSI (14)	53.35	Volatility	6.90% 6.88%
Employees	31	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	8.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	31.24%	Payout	-	Rel Volume	47.27	Prev Close	0.90
Sales Surprise	-	EPS Surprise	-4.92%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	96.75K	Price	0.98
SMA20	6.68%	SMA50	2.38%	SMA200	-11.80%	Trades		Volume	4,573,328	Change	8.87%

Today 07:30AM	MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer (GlobeNewswire) +8.87%
Apr-30-24 07:30AM	MiNK to Provide Corporate Update and First Quarter 2024 Financial Report (GlobeNewswire)
Apr-08-24 12:00PM	MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR (GlobeNewswire) -15.38%
Mar-25-24 12:00PM	All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy (Zacks) +5.47%
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:06PM	Loading…
Mar-21-24 11:06PM	Q4 2023 Mink Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:53AM	INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	MiNK Reports Fourth Quarter and Year-End 2023 Results (GlobeNewswire)
Mar-07-24 07:30AM	MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (GlobeNewswire)
Mar-06-24 08:30AM	MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 (GlobeNewswire)
Feb-14-24 08:00AM	First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab (GlobeNewswire) +7.75%
Feb-06-24 08:00AM	MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications (GlobeNewswire) +10.25%
Jan-30-24 08:00AM	MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene (GlobeNewswire)
Dec-20-23 07:30AM	ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development (GlobeNewswire)
Nov-09-23 08:05AM	MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges (GuruFocus.com) -6.72%
07:00AM	Loading…
07:00AM	MiNK Therapeutics Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-03-23 12:00PM	MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire) +13.59%
Oct-30-23 08:00AM	MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update (GlobeNewswire) +7.62%
Sep-27-23 09:05AM	MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 (GlobeNewswire)
Aug-24-23 08:30AM	MiNK Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -8.24%
Aug-10-23 07:30AM	MiNK Therapeutics Reports Second Quarter 2023 Results (GlobeNewswire) +6.67%
Jul-28-23 08:30AM	MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update (GlobeNewswire)
Jun-05-23 07:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-22-23 08:30AM	MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference (GlobeNewswire) +16.85%
May-18-23 08:30AM	MiNK's Novel FAP-CAR-iNKT Presented at ASGCT (GlobeNewswire)
May-11-23 08:00AM	MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results (GlobeNewswire) +7.28%
Apr-27-23 08:30AM	MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results (GlobeNewswire) -8.29%
Apr-18-23 01:32PM	MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting (GlobeNewswire)
Apr-16-23 08:03AM	We're Keeping An Eye On MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate (Simply Wall St.)
Apr-04-23 09:55AM	MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
08:41AM	Loading…
Mar-30-23 08:41AM	Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics (Business Wire) -6.38%
Mar-29-23 12:00PM	MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-24-23 07:36AM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-21-23 08:00AM	MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-15-23 08:45AM	MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting (GlobeNewswire) -5.63%
Mar-07-23 09:00AM	MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.35%
Feb-16-23 09:28AM	MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-11-23 02:25PM	MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference (GlobeNewswire)
Dec-22-22 10:49AM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript (Insider Monkey)
Nov-17-22 09:00AM	MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference (GlobeNewswire) -5.90%
Nov-10-22 09:05AM	MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline (GlobeNewswire) -12.80%
Nov-06-22 09:39AM	Will MiNK Therapeutics (NASDAQ:INKT) Spend Its Cash Wisely? (Simply Wall St.)
Nov-03-22 08:00AM	MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results (GlobeNewswire) +5.63%
Oct-20-22 09:00AM	MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Oct-05-22 09:16AM	MiNK Therapeutics to Host R&D Event November 10, 2022 (GlobeNewswire) +6.76%
08:30AM	MiNK Selected for Five Presentations at Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Aug-31-22 09:00AM	MiNK Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +14.35%
Aug-16-22 06:16AM	Do Insiders Own Lots Of Shares In MiNK Therapeutics, Inc. (NASDAQ:INKT)? (Simply Wall St.)
Aug-09-22 08:00AM	MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 08:30AM	MiNK Therapeutics to Participate at BTIG Biotechnology Conference (GlobeNewswire)
Jul-27-22 08:30AM	MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update (GlobeNewswire) +6.06%
May-25-22 08:30AM	MiNK Therapeutics Announces Virtual Annual Shareholders Meeting (GlobeNewswire)
May-10-22 08:00AM	MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report (GlobeNewswire) -13.64%
May-09-22 08:43AM	Here's Why We're Not Too Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Situation (Simply Wall St.) -9.74%
Apr-27-22 05:19PM	MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update (GlobeNewswire) +15.25%
Mar-18-22 08:30AM	MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-03-22 04:35PM	MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update (GlobeNewswire)
09:28AM	MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers (GlobeNewswire)
Mar-01-22 08:00AM	Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report (GlobeNewswire)
Jan-15-22 07:47AM	Could The MiNK Therapeutics, Inc. (NASDAQ:INKT) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jan-12-22 09:41AM	MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference (GlobeNewswire) +7.69%
Nov-17-21 04:15PM	MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.01%
Nov-12-21 07:30PM	Agenus inc (AGEN) Q3 2021 Earnings Call Transcript (Motley Fool) -18.12%
07:00AM	MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797 (GlobeNewswire)
Nov-09-21 08:00AM	MiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021 (GlobeNewswire)
08:00AM	Agenus Corporate Update and Third Quarter 2021 Financial Report (GlobeNewswire)
Oct-19-21 04:25PM	MiNK Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire)
Oct-15-21 05:31PM	Paragon 28 Stock Gains in Trading Debut, While MiNK Rebounds (Barrons.com)
Oct-14-21 08:29PM	MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AGENUS INC	10% Owner	Oct 16 '23	Buy	1.10	429	472	21,772,863	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 13 '23	Buy	1.10	19,373	21,310	21,772,434	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 12 '23	Buy	1.10	3,173	3,488	21,753,061	Oct 16 05:49 PM
AGENUS INC	10% Owner	Oct 04 '23	Buy	1.09	15,001	16,380	21,749,888	Oct 06 04:26 PM
AGENUS INC	10% Owner	Aug 29 '23	Buy	1.52	29,678	45,016	21,734,887	Aug 31 05:53 PM
AGENUS INC	10% Owner	Aug 28 '23	Buy	1.45	12,808	18,570	21,705,209	Aug 28 05:15 PM
AGENUS INC	10% Owner	Aug 24 '23	Buy	1.54	170,244	262,908	21,692,401	Aug 28 05:15 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

AGEN

Agenus Inc

INKT

MiNK Therapeutics Inc

Upgrade your FINVIZ experience